Actively Recruiting
A Real-world Study on the Influencing Factors of the Efficacy of Ruxolitinib Cream in the Treatment of Vitiligo
Led by Peking University Third Hospital · Updated on 2026-01-02
170
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Vitiligo is a common chronic autoimmune skin condition causing white patches on the skin that can affect any area of the body and significantly reduce quality of life. Current treatments like topical medications, phototherapy, systemic therapy, and surgery often have limited success and high rates of recurrence. This research focuses on studying ruxolitinib cream, a JAK inhibitor, to understand what factors influence its effectiveness in treating vitiligo in a real-world setting. Participants in this observational study will use ruxolitinib cream twice daily. The study aims to assess the cream's impact on vitiligo by measuring improvements in skin depigmentation using tools like the total vitiligo area scoring index (T-VASI) and the facial vitiligo area scoring index (F-VASI) over 24 weeks. Secondary assessments include patient-reported noticeability of vitiligo patches and quality of life changes. During the study, participants will be monitored at weeks 12 and 24 for changes in vitiligo severity and quality of life. Researchers will evaluate clinical differences between those achieving significant improvement and those who do not. Participants must agree to stop other vitiligo treatments during the study and use effective contraception if applicable. The total participation duration extends over 24 weeks with scheduled assessments to track treatment response and safety.
CONDITIONS
Brief Title
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 12 years or older, any gender
- Signed informed consent form
- Clinically diagnosed with non-segmental vitiligo
- Vitiligo area less than 10% of body surface area
- Agreed to stop all other vitiligo treatments from screening until final follow-up
- For females: no pregnancy or oocyte donation planned during study and use highly effective contraception
- For males: no fertility or sperm donation planned during study and use highly effective contraception
You will not qualify if you...
- Allergy to ruxolitinib cream
- Pregnant or breastfeeding women
- Any condition that the investigator considers unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 weeks
Participants apply ruxolitinib cream twice per day to affected skin areas to treat vitiligo.
Visits at Week 12 and Week 24 for assessments
Trial Site Locations
Total: 1 location
1
Peking University Third Hospital
Beijing, China, 100191
Actively Recruiting
Research Team
J
Jinzhu Guo, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here